[24] Borba MGS, Val FFA, Sampaio VS. Effect of high vs.

low doses of chloroquine diphosphate as adjunctive therapy for patients

hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA
network open 2020; 3(4): e208857.
[25] Roden D. The long QT syndrome and torsades de pointes: basic and clinical aspects Cardiac pacing and electrophysiology
1991265-83.
[26] Drew BJ, Ackerman MJ, Funk M, et al. American Heart Association Acute Cardiac Care Committee of the Council on Clinical
Cardiology, the Council on Cardiovascular Nursing, and the American College of Cardiology FoundationPrevention of torsade de
pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology
Foundation. Circulation 2010; 121(8): 1047-60.[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192704] [PMID: 20142454]
[27] White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 2007; 7(8): 549-58.[http://dx.doi.org/10.1016/S1473-3099(07)70187
-1] [PMID: 17646028]
[28] Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M, Suter W. Inhibition of hERG K+ currents by antimalarial
drugs in stably transfected HEK293 cells. Eur J Pharmacol 2004; 484(1): 41-8.[ http://dx.doi.org/10.1016/j.ejphar.2003.11.003 ]
All rights reserved. May not be reproduced in any form without permission from the publisher, except fair uses permitted under U.S. or applicable copyright law.

[PMID: 14729380]
[29] Capel RA, Herring N, Kalla M, et al. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If:
Novel electrophysiological insights and therapeutic potential. Heart Rhythm 2015; 12(10): 2186-94.[http://dx.doi.org/10.1016/j.hrthm
.2015.05.027] [PMID: 26025323]
[30] Ursing J, Rombo L, Eksborg S, et al. High-dose chloroquine for uncomplicated plasmodium falciparum malaria is well tolerated and
causes similar QT interval prolongation as standard-dose chloroquine in children. Antimicrob Agents Chemother 2020; 64(3):
e01846-19.[http://dx.doi.org/10.1128/AAC.01846-19] [PMID: 31907183]
[31] O’Laughlin JP, Mehta PH, Wong BC. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to
hydroxychloroquine. Case reports in cardiology 2016; 2016[http://dx.doi.org/10.1155/2016/4626279]
[32] Wroblewski HA, Kovacs RJ, Kingery JR, Overholser BR, Tisdale JE. High risk of QT interval prolongation and torsades de pointes
associated with intravenous quinidine used for treatment of resistant malaria or babesiosis. Antimicrob Agents Chemother 2012;
56(8): 4495-9.[http://dx.doi.org/10.1128/AAC.06396-11] [PMID: 22615288]
[33] Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without
concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol
2020; 5(9): 1036-41.[http://dx.doi.org/10.1001/jamacardio.2020.1834] [PMID: 32936252]
[34] Bessière F, Roccia H, Delinière A, et al. Assessment of QT Intervals in a case series of patients with coronavirus disease 2019
(COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA
Cardiol 2020; 5(9): 1067-9.[http://dx.doi.org/10.1001/jamacardio.2020.1787] [PMID: 32936266]
[35] Saleh M, Gabriels J, Chang D, et al. The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in
patients with SARS-CoV-2 infection. Circ Arrhythm Electrophysiol 2020; 13(6): e008662.[http://dx.doi.org/10.1161/CIRCEP.120
.008662] [PMID: 32347743]
[36] Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with
hydroxychloroquine/azithromycin. Heart Rhythm 2020; 17(9): 1425-33.[http://dx.doi.org/10.1016/j.hrthm.2020.05.014] [PMID:
32407884]
[37] Ramireddy A, Chugh H, Reinier K, et al. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019
Pandemic: Implications for QT Interval Monitoring. J Am Heart Assoc 2020; 9(12): e017144.[http://dx.doi.org/10.1161/JAHA.120
.017144] [PMID: 32463348]
[38] Mahevas M, Tran V-T, Roumier M. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19
infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial 2020.
[39] Perinel S, Launay M, Botelho-Nevers É, et al. Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19
patients. Clin Infect Dis 2020; 71(16): 2227-9.[http://dx.doi.org/10.1093/cid/ciaa394] [PMID: 32255489]
Copyright 2021. Bentham Science Publishers Ltd.

[40] Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of
hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020; 50(4): 384.[http://dx.doi.org
/10.1016/j.medmal.2020.03.006] [PMID: 32240719]
[41] Voisin O, Lorc’h EL, Mahé A, et al. Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the
Context of COVID-19 Infection. Mayo Clin Proc 2020; 95(8): 1696-700.[http://dx.doi.org/10.1016/j.mayocp.2020.05.005] [PMID:
32753141]
[42] Cipriani A, Zorzi A, Ceccato D, et al. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with
hydroxychloroquine and azithromycin. Int J Cardiol 2020; 316: 280-4.[http://dx.doi.org/10.1016/j.ijcard.2020.05.036 ] [PMID:
32439366]

EBSCO Publishing : eBook Collection (EBSCOhost) - printed on 7/12/2022 9:12 AM via ZENDY SAUDI ARABIA
AN: 2938746 ; Jean-Marc, Sabatier.; Coronaviruses
Account: ns318074.main.ehost 25